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DOI 10.1016/j.ccr.2011.05.026SUMMARYEndocrine therapies for breast cancer that target the estrogen receptor (ER) are ineffective in the 25%–30%
of cases that are ER negative (ER–). Androgen receptor (AR) is expressed in 60%–70% of breast tumors,
independent of ER status. How androgens and AR regulate breast cancer growth remains largely unknown.
We find that AR is enriched in ER– breast tumors that overexpress HER2. Through analysis of the AR cistrome
and androgen-regulated gene expression in ER–/HER2+ breast cancers we find that AR mediates ligand-
dependent activation of Wnt and HER2 signaling pathways through direct transcriptional induction of
WNT7B and HER3. Specific targeting of AR, Wnt or HER2 signaling impairs androgen-stimulated tumor
cell growth suggesting potential therapeutic approaches for ER–/HER2+ breast cancers.INTRODUCTION
Sex steroid hormones are critical for the development and
progression of cancers of reproductive organs including the
uterus and breast in women and the prostate in men. Although
estrogen is considered to be a female-selective sex steroid
and androgen a male one, both are present and play important
developmental functions in both sexes. Whereas estrogen is
widely recognized for its role in breast cancer, little is known
concerning a potential role for androgen in this disease. Steroid
hormone receptors are crucial components of steroid hormone
signaling that act as transcription factors to regulate gene
expression; however, their function contributes to hormonal
carcinogenesis. Studies of estrogen and estrogen receptor
(ER) have led to significant progress in the development of endo-
crine therapies targeting estrogen production or ER for both
breast cancer treatment and prevention. However, there areSignificance
Endocrine therapies that target the estrogen receptor (ER) are t
patients. However, 25%–30% of breast tumors do not express
The androgen receptor (AR) is also expressed in a majority of b
seq technology with genome-wide analysis of gene expressio
AR in regulating oncogenic Wnt and HER2 signaling in breast c
breast cancers. Our findings provide evidence that drugs targe
therapies for ER-negative breast cancers harboring HER2 ovecurrently no effective endocrine therapies for the 25%–30% of
breast cancers that are ER-negative (ER–).
In addition to defining breast cancers based on their expres-
sion of ER, the recognition of the role played by amplification
of the HER2 oncogene has had a major impact on the disease.
Therapies targeting HER2 such as trastuzumab are becoming
increasingly important in the treatment of HER2+ tumors of
all stages. Nonetheless, despite endocrine therapies for ER+
tumors and HER2-targeted therapies for HER2+ tumors, signifi-
cant numbers of breast tumors fail to respond. Recent studies
have found that the androgen receptor (AR) is expressed in
60%–70% of breast cancers regardless of ER status (Agoff
et al., 2003; Kuenen-Boumeester et al., 1996; Niemeier et al.,
2010). It has been postulated that AR functions as an anti-prolif-
erative effecter in ER+ breast cancer by antagonizing ER (Peters
et al., 2009), whereas it facilitates tumor cell growth in an
androgen-dependent manner in an ER–/AR+ breast cancer cellhe cornerstone of breast cancer treatment for themajority of
ER and are not responsive to existing endocrine therapies.
reast tumors, even in those that lack ER. By coupling ChIP-
n, we have identified a previously unappreciated function of
ancer leading to androgen-stimulated growth of ER–/HER2+
ting AR and the AR-regulated signaling cascade are potential
rexpression.
Cancer Cell 20, 119–131, July 12, 2011 ª2011 Elsevier Inc. 119
Figure 1. Androgen Receptor Is Function-
ally Active in ER–/HER2+ Breast Cancer
(A) Heatmap of a breast cancer microarray data
set (Wang et al., 2005a) showing the expression
levels of ERBB2/HER2, ESR1, AR, and FOXA1
across the five breast cancer subtypes classified
by the PAM50 gene signature. The AR expression
is highly correlated with HER2 status of ER–
breast tumors (rPearson > 0.69, p < 6.6 3 10
11).
(B) DHT stimulates the growth of MDA-MB-453
breast cancer cells and the AR antagonist bica-
lutamide (Bic) abrogates this effect. Data repre-
sent means +/ standard deviation (SD) from
three independent replicates. Unpaired two-tail t
test was used to examine the statistical difference
and p-values are shown.
(C) Annexin-V apoptosis assay detects increased
apoptosis induced by bicalutamide (Bic) in MDA-
MB-453 breast cancer cells.
(D) Venn diagram showing the overlap between
AR cistromes from MDA-MB-453 breast cancer
cells and LNCaP prostate cancer cells (Wang
et al., 2009) together with the ER cistrome from
MCF7 breast cancer cells (Ross-Innes et al.,
2010).
(E) Enrichment for the AR and FOXA1 binding
motifs in the center of the AR binding sites spe-
cific to MDA-MB-453 cells. The occurrence of the
motifs (N motifs) was normalized to the number of
sites of the AR cistrome (N binding sites).
See also Figure S1.
Cancer Cell
AR Regulates Oncogenic Signaling in Breast Cancerline model (Doane et al., 2006). The ER–/AR+ subclass was
previously identified as a group of breast tumors with histological
apocrine features and termed the molecular apocrine subtype
(Farmer et al., 2005).Microarray analyses reveal intact and active
AR signaling in ER–/AR+ breast tumors (Doane et al., 2006).
However, the mechanism by which AR contributes to breast
cancer development and progression is unknown. To compre-
hensively decipher the role of AR in breast cancer, we used an
integrative analysis of the AR cistrome together with androgen-
regulated gene expression profiles to define the important AR
regulated pathways that are involved in stimulating the growth
of ER–/HER2+ breast cancers.
RESULTS
AR Collaborates with FOXA1 in Global Transcriptional
Activation of Androgen-Regulated Genes
Gene expression microarray studies provide an important tool
for tumor classification, prognosis and as a guide to therapy.120 Cancer Cell 20, 119–131, July 12, 2011 ª2011 Elsevier Inc.We began by analyzing published micro-
array data sets (Hess et al., 2006; Ivshina
et al., 2006; Wang et al., 2005a) of breast
tumors to gain an overall view on AR
gene expression across different molec-
ular subtypes in breast cancer. Using
a 50-gene signature (PAM50)-based
subtype classification (Hu et al., 2006;
Parker et al., 2009; Sørlie et al., 2001,
2003), we assigned the tumor samplesinto five subclasses (Luminal A, Luminal B, normal-like, basal-
like, and HER2-enriched) and the gene expression level of AR
together with the important biomarkers, ER, FOXA1, and
HER2, are summarized in a heatmap (Figure 1A). Interestingly,
we observed a high level of AR expression in HER2-enriched
tumors. Importantly, within ER-negative subgroup that contains
both basal-like and ER–/HER2+ tumors, high AR expression is
correlatedwithHER2amplification andoverexpression (rPearson >
0.69, p < 6.6 3 1011). Consistent with this observation, recent
immunohistochemical studies also suggested a significant cor-
relation of AR with HER2 overexpression in ER-negative breast
tumors (Agoff et al., 2003; Niemeier et al., 2010; Park et al.,
2010). Notably AR is not highly expressed in the basal-like
subtype.
To understand the genomic action of androgens and AR in
ER–/HER2+ breast cancer, we investigated the gene expression
profiles of MDA-MB-453 human breast cancer cells treated with
5a-dihydrotestosterone (DHT). This ER–/HER2+ breast cancer
cell line belongs to HER2-enriched subtype based on the
Figure 2. FOXA1 Collaborates with AR in Control of DHT Signaling in ER–/HER2+ Breast Cancer
(A) Comparison ofAR and FOXA1 expression between ER–/HER2+ and basal-like, luminal or normal-like breast cancer subtypes using publishedmicroarray data
sets (Hess et al., 2006; Wang et al., 2005a). Unpaired two-tail t test is used for p value calculation. The FOXA1 expression is highly correlated with AR levels within
ER– breast tumors (rPearson > 0.76, p < 2 3 10
10).
(B) Venn diagram of the overlap between AR and FOXA1 cistromes.
(C) Sitepro analysis (Shin et al., 2009) of the genome-wide correlation between AR and FOXA1 binding sites. The average ChIP-seq signal is shown for the 1-kb
region surrounding the center of AR binding sites.
(D) Venn diagram showing the overlap between hormone-stimulated FOXA1 cistromes fromMDA-MB-453 andMCF7 (Eeckhoute et al., 2009) breast cancer cells.
(E) Correlation between DHT-upregulated gene expression and binding of AR only (AR unique), FOXA1 only (FOXA1 unique), the two factors at non-overlapped
but nearby sites (AR+FOXA1), and the two factors at the overlapped sites (AR/FOXA1 overlapping), within 50 kb of the TSS of genes. p values are shown.
See also Figure S2.
Cancer Cell
AR Regulates Oncogenic Signaling in Breast CancerPAM50 gene signature. With abundant expression of AR (Doane
et al., 2006), MDA-MB-453 cells showed increased growth
responsiveness to androgens, such as DHT (Figure 1B) and the
synthetic androgen R1881 (Doane et al., 2006). Addition of bica-
lutamide, a nonsteroidal AR antagonist, abolished the DHT-
stimulated cell growth (Figure 1B) and also induced apoptosis
(Figure 1C) in MDA-MB-453 breast cancer cells. Gene expres-
sion microarray analyses identified a total of 1341 genes that
are differentially regulated by DHT (q-value % 0.05 and fold
changeR 1.5).
To identify the direct targets of AR transcriptional regulation,
we performed AR chromatin immunoprecipitation followed by
next-generation sequencing (ChIP-seq) to define the AR cis-
trome in MDA-MB-453 breast cancer cells. We identified a total
of 2406 high-confidence AR binding sites after 4 hr of androgen
stimulation (p % 1 3 105). These AR binding sites were foundpredominantly at distal intergenic and intronic regions (see Fig-
ure S1A available online) and possessed highly conserved
genomic sequences (Figure S1B). Interestingly, whereas this
AR cistrome overlaps to a small degree with the AR cistrome in
LNCaP prostate cancer cells or the ER cistrome in MCF7 ER+
breast cancer cells, the majority of the binding sites are cell-spe-
cific (Figure 1D). Thus, our study reveals a unique hormone-regu-
lated AR cistrome in ER–/HER2+ breast cancer cells. Impor-
tantly, motif enrichment analysis of the AR cistrome revealed
the presence of not only AR and other nuclear receptor binding
motifs, but also forkhead factor binding motifs including
FOXA1 (Figure 1E). Among all forkhead family transcription
factors, FOXA1 is highly expressed in HER2+ breast tumors
and associated with AR expression (rPearson > 0.76, p < 2 3
1010), as compared to basal-like tumors of the ER-negative
subgroup (Figures 1A and 2A). It is worth noting that high levelsCancer Cell 20, 119–131, July 12, 2011 ª2011 Elsevier Inc. 121
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AR Regulates Oncogenic Signaling in Breast Cancerof FOXA1 have been observed in AR+ prostate cancers (Mirose-
vich et al., 2006) and ER+ breast cancers (Lacroix and Leclercq,
2004). In addition to its expression in breast cancer, FOXA1 has
been shown to maintain ER expression during normal mammary
ductal morphogenesis (Bernardo et al., 2010) and to act as
a cell-type specific pioneer factor that facilitates recruitment of
ER and AR to their cis-regulatory elements across the genome
(Lupien et al., 2008). To gain further insight into the potential
association between FOXA1 and AR in ER–/HER2+ breast
cancer, we determined the FOXA1 cistrome in MDA-MB-453
cells and identified 7591 high-confidence FOXA1 binding sites
(p % 1 3 105). We observed a significant overlap (37%)
between the AR and FOXA1 cistromes in MDA-MB-453 breast
cancer cells (Figure 2B). Analysis of ChIP-seq signals further
verified a strong correlation and mutual enrichment between
AR and FOXA1 binding (Figure 2C). Similar to the FOXA1 cis-
tromes previously identified in MCF7 and LNCaP cells, the
FOXA1 cistrome of MDA-MB-453 cells showed predominant
enrichment in distal intergenic and intronic regulatory regions
in genome (Figure S1C). These FOXA1 binding sites were highly
conserved (Figure S1D) and significantly enriched with the
FOXA1 binding motif (Figure 2C, inset). Interestingly, we
observed a significant overlap of FOXA1 cistromes between
MDA-MB-453 and MCF7 breast cancer cells (Figure 2D),
however the overlapped AR/FOXA1 sites in MDA-MB-453 are
largely distinct from the ER/FOXA1 sites in MCF7.
To determine the functional significance of AR and FOXA1
chromatin colocalization, we examined the correlation of tran-
scription factor binding to DHT-regulated gene expression in
MDA-MB-453 breast cancer cells. The sequences of overlapped
AR/FOXA1 sites are highly conserved (Figure S2A) and overall
either AR or FOXA1 binding sites are significantly enriched
within 50 kb of transcriptional start sites (TSS) of the DHT-upre-
gulated genes (Figures S2B–S2D). This was especially true for
sites where AR and FOXA1 bound near to one another (Fig-
ure 2E). In contrast, the genes downregulated by DHT have
only FOXA1 and not AR binding sites nearby (Figures S2C and
S2D), suggesting a role of FOXA1 in maintaining basal expres-
sion of these genes and predominantly indirect mechanisms of
androgen-mediated repression in this cell type (Lupien et al.,
2008). These data indicate an important collaboration between
AR and FOXA1 in transcriptional activation of AR target genes
and androgen signaling in ER–/HER2+ breast cancer cells.
AR Activates Wnt/b-Catenin Pathway through
Transcriptional Upregulation ofWNT7B
In keeping with the finding that AR showed cell-type-specific
chromatin occupancy in breast cancer and prostate cancer cells
in response to androgen stimulation, it also regulated distinct
transcriptional programs. By defining the DHT-upregulated tran-
scriptional program in MDA-MB-453 breast cancer cells, we
found this gene signature was significantly correlated with the
published overexpression gene signatures of HER2+ breast
tumors and as well as ER+ breast tumors (Figure 3A) using
Oncomine Concepts Map analysis (Rhodes et al., 2007). In order
to determine the identity of androgen-modulated biological
pathways in MDA-MB-453 cells we performed gene set
enrichment analysis (GSEA) (Subramanian et al., 2005) of the
androgen-regulated genes. Among the highest scoring cate-122 Cancer Cell 20, 119–131, July 12, 2011 ª2011 Elsevier Inc.gories for the DHT-stimulated genes (Figure S3), we observed
significant enrichment of genes in the Wnt signaling pathway
(Figure 3B). Screening of the genes in the Wnt pathway overex-
pressed in MDA-MB-453 cells revealed the significant upregula-
tion of the canonical Wnt ligand WNT7B (Figure 3C). Analysis
of the AR cistrome identified an AR binding site within the
WNT7B gene locus (+1.5 kb of TSS) (Figure 4A). We validated
using ChIP-qPCR that the occupancy of AR at this site was
enriched only after DHT stimulation in MDA-MB-453 cells (Fig-
ure 4B). We also confirmed by RT-PCR that DHT treatment
substantially elevated the mRNA level of WNT7B (Figure 4C),
and silencing of AR effectively impeded this induction (Fig-
ure S4A). The androgen-dependent upregulation of WNT7B by
ARwas further validated in two other ER– breast cancer cell lines
HCC202 and SUM185PE, both of which express AR and showed
increased growth responsiveness to androgen stimulation (Fig-
ure S4). These data suggest that AR directly activates WNT7B
transcription in a ligand-dependent manner.
Wnt ligands are involved in the development of normal
mammary gland and increased expression of WNT1 is onco-
genic in breast cancer models in mice (Turashvili et al., 2006).
WNT7B acts in the canonical Wnt pathway and is expressed
during the stages of ductal formation and involution in mammary
gland development (Gavin and McMahon, 1992). WNT7B has
the ability to maintain mammary epithelial cells in an uncom-
mitted state (Weber-Hall et al., 1994) and its elevated expression
has been found in 10% of all breast carcinomas (Huguet et al.,
1994). We found by analyzing published breast tumor microarray
data sets (Hess et al., 2006; Ivshina et al., 2006) that WNT7B
expression is highly correlated with AR status (rPearson > 0.44,
p < 9 3 103). As a canonical Wnt ligand, WNT7B activates
TCF-regulated gene transcription in a cell-type-specific manner
through the stabilization of b-catenin (Wang et al., 2005b). Inter-
estingly, we found that DHT stimulation led to nuclear AR,
increased WNT7B protein levels and the activation of b-catenin
in MDA-MB-453 breast cancer cells, as demonstrated by the
increased protein levels of b-catenin and its active form in the
nuclear fraction (Figure 4D). Consistent with canonical Wnt
signaling b-catenin mRNA levels were not affected (Figure S4B).
To confirm whether the nuclear translocation of b-catenin is
dependent on AR-mediated WNT7B upregulation, we trans-
duced the MDA-MB-453 cells with lentiviral shRNA targeting
eitherWNT7B or AR and the subcellular localization of b-catenin
was determined by confocal microscopy. As shown in Figure 4E,
DHT treatment induced the nuclear accumulation of both b-cat-
enin and AR. In contrast, silencing ofWNT7B or AR significantly
abrogated b-catenin nuclear localization (Figure 4E), indicating
that AR and WNT7B mediate Wnt/b-catenin activation in res-
ponse to DHT.
b-Catenin Cooperates with AR in Transcriptional
Upregulation of HER3
In the canonical Wnt pathway, nuclear b-catenin is a pivotal
regulator of TCF-regulated gene transcription. b-catenin has
also been shown to act as a coregulator of AR in prostate cancer
cells to enhance the transcriptional activity of AR (Yang et al.,
2002). We detected the physical interaction between AR and
b-catenin in the nuclear extracts of MDA-MB-453 breast cancer
cells by coimmunoprecipitation (Figure 5A). However, neither
Figure 3. Characterization of DHT-Induced Gene Signature in ER–/HER2+ Breast Cancer Cells
(A) Oncomine Concepts Map analysis (Compendia Biosciences) was used to compare the DHT/AR-induced gene signature in MDA-MB-453 cells against all
published gene signatures from primary breast tumors, and reveals statistically significant correlations between DHT-induced genes specifically associated with
AR binding sites within 50 kb of their TSS and gene expression signatures of HER2+ breast tumors as well as ER+ breast tumors. (Left) The association between
molecular concepts of different gene signatures or gene sets is represented as a graph using Gephi (http://gephi.org/), in which a node represents a gene set and
significantly associated sets (q % 2.3 3 104) were connected by an edge. The node of AR-upregulated gene set was colored in red, and the nodes of over-
expression gene sets from HER2+ or ER+ breast tumors were colored in blue and green, respectively. The thickness of the edges that connect the node of AR-
upregulated gene set with other nodes is proportional to the rank of the association significance. The size of a node is proportional to the number of overlapping
genes between its corresponding gene sets and AR-upregulated gene set. The right panel presents examples of the significant correlation between the DHT/AR-
induced gene signature with the published ER+ breast cancer gene signature and HER2+ breast cancer gene signature established in two independent studies
(Minn et al., 2005; Lu et al., 2008).
(B) Plot from gene set enrichment analysis (GSEA) (Subramanian et al., 2005) showing enrichment of theWnt pathway in DHT-upregulated transcription program.
(C) Gene expression microarray heatmap showing the DHT-induced expression of genes involved in the Wnt signaling pathway.
See also Figure S3.
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AR Regulates Oncogenic Signaling in Breast CancerDHT nor recombinant WNT7B protein was able to activate the
TCF/LEF TOP-Flash reporter; instead they suppressed the lucif-
erase activity and the cotreatment displayed a synergistic inhib-
itory effect (Figure S5A). This inhibition is likely due to a previously
described mechanism in prostate cancer in which AR competes
with TCFs for limiting amounts of nuclear b-catenin, thus sup-pressing b-catenin/TCF transcriptional activity (Chesire and
Isaacs, 2002; Mulholland et al., 2003). Moreover, DHT treatment
led to decreased expression of the four TCF/LEF family genes
(Figure S5B) in MDA-MB-453 breast cancer cells, suggesting
an additional mechanism by which androgen and AR inhibit
TCF-regulated transcription.Cancer Cell 20, 119–131, July 12, 2011 ª2011 Elsevier Inc. 123
Figure 4. AR-Mediated Transcriptional Up-
regulation ofWNT7B Activates b-Catenin
(A) Schematic diagram of the AR binding site
within theWNT7B gene locus (+1.5 kb of TSS) as
defined by AR ChIP-seq.
(B) Direct AR ChIP followed by quantitative PCR
after treatment with vehicle (blue bars) or 10 nM
DHT (red bars) for 4 hr in MDA-MB-453 breast
cancer cells. Primers flanking GAPDH promoter
region were used as a control. Data represent
means with SD.
(C) WNT7B mRNA level was determined by real-
time RT-PCR after MDA-MB-453 cells were
treated with vehicle (blue bars) or 10 nM DHT (red
bars) for the indicated times. mRNA levels are
presented as means with SD.
(D) Whole cellular extracts (WCE) or nuclear
extracts (NE) from vehicle or DHT-treated MDA-
MB-453 cells were subjected to immunoblotting
for the indicated proteins.
(E) Confocal immunofluorescence microscopy
showing endogenous AR (green) and b-catenin
(red) in lentiviral shRNA-transfected MDA-MB-
453 cells after treatment with vehicle (Veh) or
10 nM DHT for 3 days in hormone-depleted
medium. DAPI staining indicates the nucleus.
Scale bars represent 20 mM.
See also Figure S4.
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AR Regulates Oncogenic Signaling in Breast CancerPhysical interaction between AR and b-catenin represents
a secondary response to androgen stimulation. Their interaction
has been previously implicated in prostate cancer progression
(Mulholland et al., 2005; Terry et al., 2006). However, the genes
coregulated by AR and b-catenin are not known. To investigate
the regulatory role of AR in collaboration with b-catenin, we
defined the AR cistrome at a late time point (16 hr) after prolonged
DHT stimulation. ARChIP-seq revealed a total of 3431 high-confi-
dence sites in MDA-MB-453 cells (p% 1 3 105). Similar to the
4 hr-AR cistrome, these 16 hr-AR sites are mainly located in distal124 Cancer Cell 20, 119–131, July 12, 2011 ª2011 Elsevier Inc.intergenic and intronic regions and are
highly enriched near the DHT-upregulated
genes (Figure 5B). Analysis of the 4 hr-AR,
16 hr-AR, and FOXA1 cistromes revealed
significant numbers of sites that were
differentially occupied by AR at 4 hr and
16 hr of DHT treatment (Figure 5C). There
was significant overlap between AR at
both time points with FOXA1. The differ-
ential androgen-stimulated AR binding
patterns at early and late time points sug-
gested a hierarchical regulatory network
involving AR, FOXA1, and other AR cofac-
tors. To investigate the potential targets
regulated by AR and b-catenin, we first
examined the overlapped sites between
16 hr-AR and FOXA1 (744 sites as shown
in Figure 5C) and the nearby genes. Inter-
estingly, gene ontology (GO) analysis
revealed that geneswith uniquely overlap-
ped 16 hr-AR/FOXA1 binding sites within
50 kb of their TSS were significantly asso-ciated with several important biological processes including most
notably ‘‘regulation of cell proliferation’’ (Figure 5D). Through
screening of the genes involved in these GO categories, we found
HER3 as a gene involved in several of the enriched biological
processes (Figure 5D, highlighted in red). Inspection of the
FOXA1 and 16 hr-AR cistromes identified a site bound by both
close to the TSS of the HER3 gene (Figure 6A). We focused on
HER3 as it encodes an important coreceptor of HER2 in HER2+
breast cancers. We demonstrated that FOXA1 binding at the
HER3 gene was dramatically increased after DHT treatment, and
Figure 5. Prolonged DHT-Stimulation Leads to a Distinct AR Cistrome in ER–/HER2+ Breast Cancer Cells
(A) Coimmunoprecipitation of endogenous AR and b-catenin from the nuclear extracts ofMDA-MB-453 breast cancer cells after 4 hr stimulationwith vehicle (Veh)
or 10 nM DHT.
(B) Correlation between DHT-regulated genes and 16 hr-AR cistrome in MDA-MB-453 breast cancer cells.
(C) Venn diagram showing the overlap between AR and FOXA1 cistromes in MDA-MB-453 breast cancer cells.
(D) Functional annotation of the genes that uniquely possess overlapped 16 hr-AR and FOXA1 binding sites. Top overrepresented gene categories (p% 0.05) from
gene ontology (GO) biological process are shown and the categories involving HER3 are colored in red.
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AR Regulates Oncogenic Signaling in Breast Cancerconcomitantly, a substantially enhanced occupancy of both AR
and b-catenin was also verified at this same region in MDA-MB-
453 (Figure 6B) and as well SUM185PE breast cancer cells
(Figure S5E).
Sequence analysis of this overlapped AR/FOXA1 region
revealed two FOXA1 binding motifs and one ARE half-site motif
nearby (Figure S5C). Additionally, three TCF4/TCF7L2 motifs
also occur within this 950-bp region (Figure S5C, blue boxes).
Given that TCF factors recruit b-catenin to chromatin as part of
canonical Wnt signaling and DHT downregulates TCF expres-
sion in MDA-MB-453 breast cancer cells, we speculated that
TCF4 might initially reside at this regulatory region of the HER3
gene before AR activation, and may recruit b-catenin together
with AR on DHT stimulation. Consistent with this hypothesis,
TCF4 ChIP showed that TCF4 was able to occupy the same
region in the absence of DHT, whereas the recruitment of
TCF4 to HER3 gradually declined after DHT stimulation (Fig-
ure S5D), likely due to the DHT-mediated downregulation of
TCFs in MDA-MB-453 cells as described above. Androgen stim-
ulation led to increased expression of HER3, which was abro-
gated by silencing of AR or b-catenin (Figures 6C and 6D). As ex-
pected, AR silencing caused a decrease in b-catenin at protein
levels; interestingly, b-catenin knockdown also diminished AR
expression in MDA-MB-453 cells (Figure 6D). This observation
implicated a feedback mechanism between Wnt/b-catenin and
androgen/AR pathways. In prostate cancer cells, it has been
suggested that Wnt signaling modulates AR transcriptionalactivity and protein stability by multiple pathways (reviewed in
Terry et al., 2006), including direct regulation of AR transcription
and protein stability by b-catenin/TCF (Yang et al., 2006). These
findings indicate a regulatory mechanism by which androgen
induces HER3 expression in ER–/HER2+ breast cancer cells
through collaboration between AR and b-catenin.
HER3 together with EGFR/HER1, HER2, and HER4 consti-
tutes the HER family of tyrosine kinases. It is through dimeriza-
tion and transphosphorylation that the HER members trigger
signaling cascades. Importantly, HER2 activation requires het-
erodimerization with another HER receptor due to its lack of
ligand binding activity (Baselga and Swain, 2009). The signifi-
cance of HER3 in HER2+ breast tumors is well recognized for
its ability to form heterodimers with HER2 and modulate the
PI3K/AKT pathway (reviewed in Baselga and Swain, 2009).
HER3 is thought to be an important determinant of the onco-
genic activity of HER2 in breast cancer (Hsieh and Moasser,
2007; Lee-Hoeflich et al., 2008). It has been shown that
increased HER3 expression substantially augments HER2
signaling, and contributes to the incomplete inhibition of HER2
activity by tyrosine kinase inhibitors (Sergina et al., 2007). Simi-
larly, we observed that the phosphorylation of both HER3 and
HER2 was elevated as an indication of the active HER2
signaling pathway during DHT treatment (Figure 6E). As a down-
stream event of HER2/HER3 signaling, the PI3K/AKT pathway
was also significantly activated in response to androgen,
demonstrated by the increased phosphorylation of AKTCancer Cell 20, 119–131, July 12, 2011 ª2011 Elsevier Inc. 125
Figure 6. AR-Regulated HER3 Induction
Activates HER2/HER3 Signaling Pathway
in ER–/HER2+ Breast Cancer Cells
(A) Schematic representation showing the over-
lapped AR and FOXA1 binding site within the
HER3 gene locus as defined by ChIP-seq in MDA-
MB-453 breast cancer cells.
(B) Recruitment of FOXA1, AR, and b-catenin to
the regulatory region of HER3 (+1.8 kb of TSS).
Direct ChIP-qPRC of FOXA1, AR and b-catenin
was performed to monitor their binding at HER3
gene after MDA-MB-453 cells were treated with
vehicle or 10 nM DHT for 4 hr or 16 hr. Data
represent means with SD.
(C) MDA-MB-453 cells transduced with the indi-
cated shRNA lentivirus were treated with vehicle
or DHT for 16 hr, and the total RNA was subjected
to real-time RT-PCR of HER3. mRNA levels are
presented as means with SD.
(D) Immunoblotting to determine HER3 expression
in MDA-MB-453 cells after transduction of the
indicated lentiviral shRNA followed by vehicle (–) or
DHT (+) treatment for 16 hr in hormone-depleted
medium.
(E) MDA-MB-453 breast cancer cells were treated
with 10 nM DHT for the indicated times and as-
sayed for expression and phosphorylation of the
indicated proteins.
(F) Lentiviral shRNA-transduced MDA-MB-453
cells were cultured in hormone-depleted medium
for 2 days followed by treatment with vehicle (Veh)
or 10 nMDHT for the indicated time points, and the
total numbers of viable cells were determined. The
results are shown as means +/– SD from three
independent replicates.
(G) MDA-MB-453 cells were treated with the
indicated agents for 48 hr and HER3 and HER3
phosphorylation were measured by immuno-
blotting.
(H) After treatment with the indicated inhibitors in
the presence of vehicle or 10 nM DHT for 3 days,
the total numbers of viable cells were determined
and the means from three independent replicates
are shown with SD.
See also Figure S5.
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AR Regulates Oncogenic Signaling in Breast Cancer(Figure 6E) in MDA-MB-453 cells. Activation of this signaling
cascade was also observed in DHT-stimulated SUM185PE
breast cancer cells (Figure S5F). These observations indicate
that the elevated expression of HER3 in response to androgen
leads to enforced HER2/HER3 signaling in ER–/HER2+ breast
cancer cells.126 Cancer Cell 20, 119–131, July 12, 2011 ª2011 Elsevier Inc.Targeting Androgen-Induced
HER2/HER3 Activation Impairs
Tumor Cell Growth
HER3-mediated PI3K/AKT activation is
crucial for maintaining cell proliferation
and survival. Thus, we hypothesized that
AR/b-catenin-mediated upregulation of
HER3 and activation of HER2/HER3
signaling might account for increased
cell growth after androgen stimulation.
Consistent with this hypothesis, silencingof AR, WNT7B or b-catenin effectively impeded the DHT-
induced cell growth (Figure 6F), confirming the important func-
tion of AR and WNT7B/b-catenin in ER–/HER2+ breast cancer.
To gain further insights into the effects of antagonizing AR and
the AR-regulated signaling cascade in ER–/HER2+ breast
cancer, we tested the pharmacological inhibitors targeting AR
Figure 7. Coexpression of AR and HER3 in
ER–/HER2+ Breast Tumors
(A) Comparison of HER3 expression between ER–/HER2+
and basal-like breast cancer subtypes using published
microarray data sets (Hess et al., 2006; Wang et al.,
2005a). Unpaired two-tail t test is used for p value calcu-
lation. The HER3 expression is highly correlated with
AR levels of ER–/HER2+ tumors (rPearson > 0.41, p <
2.8 3 104).
(B) Representative AQUA output images of tissue micro-
array staining analysis for the four subtypes of ER–/PR–
breast tumors based on AR (cutpoint >800) and HER2
status. AQUA scores are shown and the scale bars
represent 100 mM.
(C) Quantitation of HER3 staining in the four subtypes,
HER2–/AR– (n = 93), HER2–/AR+ (n = 12), HER2+/AR–
(n = 32) and HER2+/AR+ (n = 10) of ER–/PR– breast tumor
samples by AQUA. p values were based on two-sided
testing, and p < 0.05 was considered as statistically
significant.
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AR Regulates Oncogenic Signaling in Breast Cancer(bicalutamide), Wnt/b-catenin (IWP2 and IWR1) (Chen et al.,
2009), or HER2 (tyrosine kinase inhibitors lapatinib and
GW583340) in cell growth assays. Inhibitors targeting AR and
Wnt/b-catenin pathways were able to abolish the DHT-induced
recruitment of AR and b-catenin to the HER3 gene (Figure S5H),Cancer Cell 20which blocked induction of HER3 at mRNA
level (Figure S5I). We further demonstrated
that these inhibitors targeting AR, Wnt, or
HER2 signaling greatly diminished DHT-in-
duced HER3 activation, shown as a decrease
of both total protein level and phosphorylation
of HER3 in the presence of DHT (Figure 6G). In
accordance with attenuated HER3 activity,
DHT-induced cell growth of MDA-MB-453 was
abrogated by addition of these inhibitors (Fig-
ure 6H). Similar effects were observed in
SUM185PE breast cancer cells (Figure S5G).
Notably, the tyrosine kinase inhibitors, lapatinib
and GW583340, were able to inhibit tumor cell
growth significantly only with DHT cotreatment.
This suggests that androgen stimulation in-
creases the dependence onHER2/HER3 signal-
ing for growth in ER–/HER2+ breast tumors that
express AR.
High Level of HER3 Is Correlated with AR
Expression in ER–/HER2+ Breast Tumors
Using breast cancer cell lines, we identified
HER3 as a downstream target of AR. To deter-
mine whether HER3 is also highly expressed in
clinical ER–/HER2+ breast tumors, we first
analyzed the published gene expression micro-
arrays of breast tumor samples. Analysis of
two independent data sets revealed signifi-
cantly higher levels of HER3 expression in
ER–/HER2+ breast tumors compared to basal-
like ones (Figure 7A) and importantly HER3
expression is highly correlated with AR expres-sion across all ER-negative breast tumors (rPearson > 0.41, p <
2.8 3 104). To further confirm this correlation, we performed
immunohistochemical staining of AR and HER3 in breast carci-
noma tissue microarrays and quantified the levels of AR and
HER3 proteins in human breast cancer tissues by automated, 119–131, July 12, 2011 ª2011 Elsevier Inc. 127
Figure 8. Bicalutamide Impedes DHT-
Induced Tumor Growth In Vivo
(A) Effects of DHT and bicalutamide on the growth
of MDA-MB-453 xenograft tumors. MDA-MB-453
cells were orthotopically implanted in the fourth
inguinal gland of female NOD/SCID mice and the
DHT release pellets were implanted subcutane-
ously at the same time in the surgery. Animals
bearing tumors (>400 mm3 in size) were randomly
grouped (8–10 mice/group) and treated with daily
oral gavage of vehicle or bicalutamide (10 mg/kg)
for 3 weeks. Data are presented as mean tumor
volume +/ SEM.
(B) Immunoblot analysis of MDA-MB-453 xeno-
graft tumors from different treatment groups to
examine the expression or phosphorylation of the
indicated proteins. The whole cell extracts sub-
jected to immunoblotting were prepared from
three tumor samples for each group that were
collected from three mice, respectively.
(C) The paraffin-embedded tumor sections were
subjected to histological analysis by hematoxylin
and eosin staining, immunohistochemical staining
of the indicated proteins and TUNEL assays for
in situ cell death detection. Scale bars represent
50 mM.
(D) Model of the regulatory role of AR in activating
WNT7B/b-catenin and HER2/HER3 in ER–/HER2+
breast cancer. The inhibitors targeting AR, Wnt, or
HER2 pathways are highlighted in yellow.
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AR Regulates Oncogenic Signaling in Breast Cancerquantitative analysis (AQUA) (Camp et al., 2002). Figure 7B
shows representative images from immunofluorescent labeling
of AR and HER3 in four subtypes of ER–/PR– breast tumors
classified by the expression of HER2 and AR. Each panel shows
the AQUA score indicating the protein level of AR or HER3. AR
expression is predominantly nuclear and HER3 expression was
both membranous and cytoplasmic, notably excluded from the
nuclear compartment (non-nuclear). The quantitative analysis
demonstrated significantly higher HER3 expression in HER2+/
AR+ breast tumors as compared to the other ER–/PR– subtypes
(Figure 7C). Thus these analyses in breast cancer patient
samples demonstrate that HER3 expression is correlated with
AR and HER2 status in ER-negative breast cancers and support
our finding that HER3 is a direct AR target.
Bicalutamide Inhibits the Growth of DHT-Stimulated
ER–/HER2+ Breast Tumors In Vivo
To determine the antitumor effect of targeting AR in vivo, we es-
tablished an MDA-MB-453 xenograft model. The MDA-MB-453
cells were implanted in the mammary gland of NOD/SCID mice,
and one group of the mice received the concomitant implanta-
tion of a DHT slow-release pellet. DHT dramatically promoted128 Cancer Cell 20, 119–131, July 12, 2011 ª2011 Elsevier Inc.the growth of MDA-MB-453 tumors
in vivo (p = 0.0003) (Figure 8A). After
tumors reached a volume of 400 mm3,
daily oral administration of bicalutamide
at 10 mg/kg was delivered to 50% of
the mice carrying DHT pellets (n = 8).
As expected bicalutamide treatment
resulted in a significant inhibition ofDHT-stimulated growth of MDA-MB-453 xenograft tumors
(p = 0.0007) and tumors regressed to control levels after 3 weeks
of treatment (Figure 8A).
Immunoblot analysis of MDA-MB-453 tumor extracts
confirmed that AR levels were elevated by DHT treatment
in vivo. Consistent with our cell culture findings, the AR-regu-
lated Wnt/b-catenin and HER2/HER3 signaling pathways were
substantially induced in the tumors from the mice carrying DHT
pellets, whereas bicalutamide treatment abrogated the DHT-
induced activation of these pathways (Figure 8B). Hematoxylin
and eosin staining of paraffin-embedded tumor sections re-
vealed that whereas MDA-MB-453 xenografts exhibited well-
organized sheets of round and cohesive undifferentiated tumor
cells, the tumors treated with bicalutamide showed more disco-
hesive cells within a disordered structure (Figure 8C). Tumor
sections from each treatment group were further analyzed by
immunohistochemical staining of AR and its targets to determine
the effects of DHT and bicalutamide on their expression in vivo.
Importantly, the DHT-treated xenograft tumors showed signifi-
cant nuclear AR and membranous HER2 staining, and elevated
HER3 and p-AKT levels as compared to the tumors from the
mice without DHT pellets. Significantly, bicalutamide treatment
Cancer Cell
AR Regulates Oncogenic Signaling in Breast Cancerled to substantial reduction in expression of HER3 and p-AKT,
and enhanced cell death as detected by TUNEL assay (Fig-
ure 8C). Taken together, these results demonstrate that inhibiting
AR with bicalutamide blocked androgen-stimulated oncogenic
HER2/HER3 signaling and inhibited the growth of ER–/HER2+/
AR+ breast tumors in vivo.
DISCUSSION
Endocrine therapies that target estrogen and ER signaling
pathways play a critical role in the treatment of the majority of
breast cancer patients. However, over a quarter of breast tumors
fail to express ER and are thus resistant to these therapies. Our
findings suggest that there are a significant number of ER–/
HER2+ breast tumors that express AR and are growth stimulated
by androgens. We have shown that androgens and AR stimulate
oncogenic Wnt and HER2 signaling pathways by transcriptional
upregulation ofWNT7B and HER3 in ER–/HER2+ breast cancer
(as summarized in Figure 8D), by which androgen stimulates
tumor cell growth. This regulatory network indicates an intrinsic
link between AR and growth factor pathways in ER-negative
breast cancer.
Hormonal regulation of Wnt expression has been suggested in
mammary gland development, such as WNT4 by progesterone
(Brisken et al., 2000), and WNT5B and WNT7B by human
chorionic gonadotropin (hCG) (Kuorelahti et al., 2007), whereas
the direct effect of androgen and AR on WNT expression was
previously unknown in the normal mammary gland or breast
tumors. Overexpression of Wnt causes aberrant activation of
the Wnt signaling pathway, which is a major driving force in
a broad spectrum of human cancers. In this study, we have
shown that AR-stimulated elevation ofWNT7B leads to activated
nuclear translocation of b-catenin. This in turn leads to b-catenin
interaction with AR to induceHER3 gene expression. These find-
ings highlight a crucial androgen-dependent signaling cascade
that is regulated by AR in ER–/HER2+ breast cancer. The nuclear
localization of b-catenin is an important predictor of poor prog-
nosis and outcome in colorectal cancer. However, the subcel-
lular location of b-catenin has not been well investigated in
breast cancer. We find that the collaboration between b-catenin
and AR together with FOXA1 plays an important role in ER–/
HER2+ breast tumors through binding to regulatory regions of
the HER3 gene.
HER3 is receiving increased attention as a therapeutic target in
HER2+ breast cancers. Clinical studies of EGFR and HER2
antagonists suggest that HER2+ breast cancer is primarily
drivenbyHER2/HER3heterodimers rather thanHER2/EGFRhet-
erodimers (reviewed in Baselga and Swain [2009]). Interfering
with HER2/HER3 heterodimerization has been suggested as an
option to inhibit HER3 activation with the development of agents
such as pertuzumab. Our work indicates that targeting AR with
antagonists such as bicalutamide, may be another way to target
HER3. Clinical trials of the anti-androgen bicalutamide in ER–/
AR+ metastatic breast cancer are ongoing (NCT00468715). Our
study also suggests that pharmacological inhibitors targeting
AR-regulated pathways will only be effective in the presence of
active androgen signaling and may be limited to ER–/HER2+
tumors. Expression of androgen/AR-regulated genes in ER–/
HER2+ breast tumors could be predictors of a therapeuticresponse to AR target therapies. It has been shown that the
signaling pathways including Wnt, HER2 and PI3K/AKT are able
to actively enforce AR activity, constituting positive feed-forward
circuits (Mellinghoff et al., 2004; Mulholland et al., 2006; Terry
et al., 2006). This may potentially lead to androgen-independent
AR activation in breast tumors, as has been demonstrated in
castration-resistant prostate cancer (Wang et al., 2009). Collec-
tively, this work provides not only novel insights into androgen-
dependent AR function in breast cancer, but also reveals the
mechanistic basis for targeting AR as a therapeutic opportunity
for patients with invasive ER–/HER2+ breast tumors.
EXPERIMENTAL PROCEDURES
Gene Expression Microarray Analysis
Hormone-depleted MDA-MB-453 cells were treated with vehicle or 10 nM
DHT for 4, 16, or 48 hr, and the total RNA was isolated and hybridized to Affy-
metrix human U133 plus 2.0 expression array. All Gene expression microarray
data were normalized and summarized using RMA (Irizarry et al., 2003). The
differentially expressed genes betweenDHT and vehicle conditions were iden-
tified using SAM algorithm (Tusher et al., 2001) that is implemented in the MeV
program (Saeed et al., 2006) (q % 0.05, fold change R 1.5). The raw data of
breast tumor microarray were obtained from previous publication (Hess
et al., 2006; Ivshina et al., 2006;Wang et al., 2005a) and were normalized using
RMA (Irizarry et al., 2003). The intrinsic subtype of individual breast tumor
sample in clinical data sets was assigned using a 50-gene signature
(PAM50) based on a supervised approach (Parker et al., 2009). The coexpres-
sion between AR and HER2, FOXA1, HER3, or WNT7B across breast tumor
subtypes was characterized using Pearson correlation coefficient. The differ-
entially expressed genes between different subtypes were identified using
Welch’s t test (q% 0.05).
ChIP and ChIP-Seq
ChIP was performed as previously described (Carroll et al., 2005) and the AR
and FOXA1 ChIP-seq experiments were performed in hormone-depleted
MDA-MB-453 cells with 10 nM DHT exposure. Briefly, 5–10 3 106 cells were
cross-linkedwith 1% formaldehyde for 10min at room temperature. Chromatin
was sonicated in SDS lysis buffer to 300–500 bp. Antibodies were incubated
with sonicated chromatin overnight, followed by incubation with Dynabead
Protein A (Invitrogen) for 4 hr for chromatin collection. Concentrations of the
ChIPDNAwerequantifiedbyQubit Fluorometer (Invitrogen). Fifteennanograms
of the input (total sonicated chromatin DNA) or 6 ng of the ChIP samples were
subjected to poly(A) tailing process (see Supplemental Experimental Proce-
dures for details) and direct sequencing using Helicos HeliScope sequencer
at Dana-Farber Cancer Institute. The antibodies used in ChIP experiments
are AR (N-20, Santa Cruz), FOXA1 (ab-23738 from Abcam), b-catenin (H-102,
Santa Cruz), and TCF4/TCF7L2 (N-20, Santa Cruz and clone6H5-3, Millipore).
Co-IP and Immunoblot Analysis
The endogenous co-IP experiments were performed using nuclear extracts as
described previously (Xu et al., 2010). Briefly, 5 mg of nuclear extracts were
incubated with 5 mg of AR or b-catenin antibody on a rotator overnight at
4C. The protein complexes were precipitated by addition of protein G/A-
agarose beads (Roche) with incubation for 4 hr at 4C. After wash for four times
for 15 min, the beads were boiled for 5 min in protein sample buffer (Bio-Rad).
The antibodies used for IP include AR (N-20, Santa Cruz) and b-catenin (H-102,
Santa Cruz). The immunoprecipitated products or the cell lysates were pro-
cessed for immunoblot as described previously (Wang et al., 2007) using anti-
bodies against AR, HER3, TBP, and GAPDH from Santa Cruz, b-catenin and
active b-catenin from Millipore, WNT7B from Novus, p-HER3, p-HER2,
p-AKT, HER2, and AKT from Cell Signaling.
Immunohistochemical Staining and Automated Quantitative
Analysis of Tissue Microarrays
The staining of AR and HER3 was performed on the archival Yale breast carci-
noma tissue microarray cohort by a modified indirect immunofluorescenceCancer Cell 20, 119–131, July 12, 2011 ª2011 Elsevier Inc. 129
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tumor compartment of each histospot was defined using anticytokeratin
antibodies and the primary antibodies are AR (Dako AR441), and HER3
(noncommercial antibody from CST, D11E5). Secondary labeling of targets
was performed by signal amplification using horseradish peroxidase-labeled
secondary reagents (species-specific Dako Envision) followed by Cy-5 tyra-
mide incubation. DAPI in an anti-fading mounting medium was used for
nuclear staining. Automated quantitative analysis (AQUA) is a method that
allows exact and objective measurement of protein levels within a defined
tumor area, as described previously (Camp et al., 2002). All statistical analysis
was performed using Stat-View software and p values were based on two-
sided testing, and p < 0.05 was considered as statistically significant. The
tissue assessed in this study was obtained from the Yale Pathology Archives
based on Yale Human Investigation Committee protocols #9505008219,
#0304025173, and #0003011706. These protocols, to Dr. David Rimm, allow
retrieval of tissue from archives that was consented or has been approved
for use with waiver of consent.
Orthotopic Tumor Growth Assays
Six-week-old female NOD-SCID-IL2Rgc–/– mice (Jackson Lab) were used for
xenograft studies. Approximately 6 3 106 viable MDA-MB-453 cells were
resuspended in 30 ml 50% growth factor-reduced Matrigel (BD Biosciences)
and injected orthotopically into the fourth inguinal gland as previously
described (Torres-Arzayus et al., 2006). The DHT release pellet (60 day release
pellet, Innovative Research of America) was implanted subcutaneously at the
time of surgery. The mice bearing tumors >400 mm3 were randomly grouped
and treated by daily oral administration with vehicle or bicalutamide (10 mg/
kg). Tumor volume was determined by measuring the minimum and maximum
tumor diameters using the formula: (minimum diameter)2 3 (maximum diam-
eter)/2. All animal protocols were conducted with the approval of the IACUC
at Dana-Farber Cancer Institute.ACCESSION NUMBERS
Gene expression microarray and ChIP-seq data have been deposited in the
Gene Expression Omnibus database with accession number GSE28789.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/
j.ccr.2011.05.026.
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